Bausch Health Companies is a global healthcare company that focuses on developing, manufacturing, and marketing innovative pharmaceutical and medical device products
It primarily operates in the areas of eye health, dermatology, and gastrointestinal health, offering a diverse range of prescription and over-the-counter products. With a commitment to addressing unmet medical needs, Bausch Health leverages its robust research and development capabilities to enhance patient care and improve health outcomes. The company also emphasizes sustainability and ethical practices in its operations, aiming to make a positive impact on the communities it serves.
The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.
Dental supply maker Patterson Companies Inc announced Thursday that it is exploring strategic options, including a sale or merger, to boost shareholder value.
Bausch Health reports Q2 2024 GAAP EPS of $0.03, missing the consensus of $0.28. Revenue hits $2.403 billion, up 11% YoY. Piper Sandler downgrades BHC to Underweight with a price target of $3, citing concerns over debt maturing in 2027/2028 and Xifaxan's loss of exclusivity.
Bausch Health Companies Inc. (NYSEBHC) is experiencing a sharp decline in its stock price Wednesday. The drop was triggered by a report suggesting the company is negotiating a potential prepackaged Chapter 11 bankruptcy with co-op creditors.
Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market Committee (FOMC) meeting signaled a potential interest
After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a slowdown in the upward momentum is in the cards.
BHC stock results show that Bausch Health Companies missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
